Artificial intelligence screens echocardiograms to flag cardiac amyloidosis
Tests an AI tool reading heart ultrasounds to flag adults for cardiac amyloidosis screening.
Plain-language title generated from the registry record
Registry title: Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
Key facts
- Where
- Los Angeles, United StatesSee the site
Where in United States
- Cedars-Sinai Medical Centre (Los Angeles)Los Angeles, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cedars-Sinai Medical Center
- Trial code
- NCT05139797
- Record updated
- 22 July 2026
- Original description
Despite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotyping has led to a widening gap between the potential and the actual benefits realized by precision medicine.Read full original descriptionShow less
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases
Despite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotyping has led to a widening gap between the potential and the actual benefits realized by precision medicine.
Recent advances in machine learning and image processing techniques have shown that machine learning models can identify features unrecognized by human experts and more precisely/accurately assess common measurements made in clinical practice.
The investigators have developed an algorithm, termed EchoNet-LVH, to identify cardiac hypertrophy and identify patients who would benefit from additional screening for cardiac amyloidosis and will prospectively evaluate its accuracy in identifying patients whom would benefit from additional screening for cardiac amyloidosis.
Inclusion: Patients who have a high suspicion for cardiac amyloidosis by AI algorithm.
Exclusion: Patients who decline to be seen at specialty clinic; Patients who have passed away.